GLP-1 & Incretin Science

Three Head-to-Heads, One Common Comparator

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

Tirzepatide appears as the comparator in SURMOUNT-5 against semaglutide, in REDEFINE 4 against CagriSema, and in TRIUMPH-5 against retatrutide. It has become the standard a new obesity compound is expected to be tested against.

Key facts

SURMOUNT-5
Tirzepatide 20.2% vs semaglutide 13.7%
REDEFINE 4
Tirzepatide 25.5% vs CagriSema 23.0%
TRIUMPH-5
vs retatrutide (primary completion scheduled Nov 2026)
REDEFINE 4 registration
NCT06131437, n=809, completed
TRIUMPH-5 registration
NCT06662383, n=800, active
Common feature
Tirzepatide is the reference arm

How a benchmark forms

A compound becomes the comparator when beating it is what the field considers meaningful. Tirzepatide reached that position by winning the one direct comparison against semaglutide that mattered: SURMOUNT-5 randomised 751 adults over 72 weeks and reported 20.2% against 13.7%. After that, showing superiority to semaglutide stopped being sufficient.

Why sponsors run these trials at all

They are risky. A head-to-head against a strong comparator can produce a result the sponsor did not want, publicly and irreversibly, as happened to Novo Nordisk in REDEFINE 4. Running one signals confidence, and prescribers and payers increasingly expect the evidence rather than accepting cross-trial comparison.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What the three trials are not

Comparable with each other. SURMOUNT-5 ran 72 weeks, REDEFINE 4 ran 84, TRIUMPH-5 is a different population again. Tirzepatide's reported figure differs between them (20.2% in one, 25.5% in another), and that difference reflects trial design, duration and population rather than the drug changing. Reading across them as a league table is the error head-to-heads exist to prevent.

Why tirzepatide's own number moves

Different durations, different populations, different estimands. In REDEFINE 4 the efficacy estimand gave 25.5% and the treatment-policy estimand 23.6%, a 1.9 point gap within one trial, from the same participants, reflecting only how discontinuation is handled. A figure quoted without its estimand cannot be compared with anything.

What TRIUMPH-5 will and will not settle

Registered as NCT06662383, active and not recruiting, 800 participants, primary completion scheduled for November 2026. Because retatrutide and tirzepatide are both Lilly molecules built on modified GIP scaffolds, the comparison isolates the glucagon receptor arm about as cleanly as a trial can. It will not tell you how retatrutide compares with CagriSema, because nobody has run that trial.

The regulatory point that gets lost

Tirzepatide and semaglutide are licensed medicines. CagriSema is filed and unapproved. Retatrutide is investigational. A table of weight-loss percentages flattens a group of compounds at completely different regulatory stages into apparent equivalents, and none of them has any relationship to research material.

Quick reference

TrialComparisonDurationStatus
SURMOUNT-5Tirzepatide vs semaglutide72 weeksReported
REDEFINE 4CagriSema vs tirzepatide84 weeksCompleted Jan 2026
TRIUMPH-5Retatrutide vs tirzepatide-Primary completion scheduled Nov 2026

Frequently asked questions

Why is tirzepatide the comparator in so many trials?

It won the direct comparison against semaglutide in SURMOUNT-5, after which beating semaglutide alone stopped being a meaningful claim.

Can I rank these compounds from the three trials?

No. Different durations, populations and estimands. Tirzepatide's own reported figure differs between them for those reasons alone.

Why do sponsors risk head-to-heads?

Prescribers and payers increasingly expect direct evidence, and running one signals confidence, though REDEFINE 4 shows the risk is real.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.